Boston Scientific(US:BSX) ZACKS·2026-01-07 00:15Company Performance - Boston Scientific (BSX) closed at $97.79, with a gain of +2.42%, outperforming the S&P 500's gain of 0.62% on the same day [1] - Prior to this trading session, BSX shares had increased by 1.75%, contrasting with the Medical sector's decline of 1.22% and the S&P 500's gain of 0.59% [1] Earnings Projections - The company is expected to release its earnings on February 4, 2026, with projected EPS of $0.78, reflecting an 11.43% increase year-over-year [2] - Revenue for the upcoming quarter is anticipated to be $5.27 billion, indicating a 15.44% increase compared to the same quarter last year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $3.04 per share, representing a +21.12% change from the previous year, while revenue is estimated at $20.06 billion, showing no change [3] - Recent analyst estimate revisions for Boston Scientific suggest positive short-term business trends, which are typically seen as favorable for the business outlook [3] Stock Valuation - Boston Scientific is currently trading at a Forward P/E ratio of 27.65, which is higher than the industry average of 19.35 [6] - The company has a PEG ratio of 1.69, compared to the Medical - Products industry's average PEG ratio of 1.71 [6] Industry Ranking - The Medical - Products industry, part of the Medical sector, has a Zacks Industry Rank of 162, placing it in the bottom 34% of over 250 industries [7] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]